Cogent Biosciences, Inc. (COGT)
Market Cap | 712.25M |
Revenue (ttm) | n/a |
Net Income (ttm) | -177.66M |
Shares Out | 86.12M |
EPS (ttm) | -2.33 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 18,070 |
Open | 8.19 |
Previous Close | 8.27 |
Day's Range | 8.13 - 8.27 |
52-Week Range | 6.43 - 15.68 |
Beta | -0.20 |
Analysts | Strong Buy |
Price Target | 22.83 (+178.08%) |
Earnings Date | Nov 2, 2023 |
About COGT
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target exon 17 mutations found within the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercializat... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for COGT stock is "Strong Buy." The 12-month stock price forecast is $22.83, which is an increase of 178.08% from the latest price.
News

Cogent Biosciences Announces Poster Presentations at Upcoming San Antonio Breast Cancer Symposium
WALTHAM, Mass. and BOULDER, Colo., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined ...

Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2023 Financial Results
SUMMIT and APEX clinical presentations planned for 2023 ASH Annual Meeting; SUMMIT NonAdvSMdata selected for oral presentation

Cogent Biosciences Presents Preclinical Data Highlighting Precision Oncology Pipeline at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
– Novel selective and reversible FGFR2 inhibitor exhibits strong potency across key primary and resistance driver mutations with potential advantages over covalent approaches –

Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2023 Financial Results
Initial clinical results from Phase 2 SUMMIT trial in NonAdvSM along with updated data from Phase 2 APEX trial in AdvSM on track for 2H 2023

3 Lost Formula Stocks to Consider for the 2nd Half of 2023
Having ended 2022 on a low note, U.S. market indexes have overall shown stronger performances so far in 2023.

Cogent Biosciences Announces Closing of Upsized Public Offering of Common Stock
WALTHAM, Mass. and BOULDER, Colo., June 09, 2023 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined ...

Cogent Biosciences Announces Participation in the Jefferies Healthcare Conference
WALTHAM, Mass. and BOULDER, Colo., June 07, 2023 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined ...

Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock
WALTHAM, Mass. and BOULDER, Colo., June 06, 2023 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined ...

Cogent Biosciences Announces Proposed Public Offering of Common Stock
CAMBRIDGE, Mass. and BOULDER, Colo., June 06, 2023 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically define...

Cogent Biosciences Announces Positive Lead-In Data from Ongoing Phase 3 PEAK Trial Evaluating Bezuclastinib in Combination with Sunitinib in Patients with Gastrointestinal Stromal Tumors (GIST)
- Data presented at ASCO annual meeting demonstrate 55% Disease Control Rate (DCR) in heavily pre-treated GIST patients, including 100% DCR and 17% overall response rate (ORR) in efficacy evaluable 2...

Cogent Biosciences to Host Investor Webcast to Discuss Lead-In Data Being Presented at ASCO from the Ongoing Phase 3 PEAK Trial in Patients with Gastrointestinal Stromal Tumors (GIST)
WALTHAM, Mass. and BOULDER, Colo.

Cogent Biosciences Reports Recent Business Highlights and First Quarter 2023 Financial Results
Lead-in data from Phase 3 PEAK trial to be presented at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting

Cogent Biosciences Presents Preclinical Data at AACR Annual Meeting Highlighting Precision Therapy Pipeline and Announces Initiation of Part 2 of the Registration-Enabling APEX Trial with Bezuclastinib in Advanced Systemic Mastocytosis
Preclinical data describes a novel EGFR-sparing, brain-penetrant ErbB2 inhibitor active against key oncogenic ErbB2 mutations

Cogent Biosciences Announces Participation at Upcoming Investor Conferences
WALTHAM, Mass. and BOULDER, Colo., April 12, 2023 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically define...

Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results
WALTHAM, Mass. and BOULDER, Colo., March 14, 2023 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically define...

Cogent Biosciences Announces Planned 2023 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Cancer Therapeutics
WALTHAM, Mass. and BOULDER, Colo., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined...

Cogent Biosciences Announces Presentation at the 41st Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass. and BOULDER, Colo., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined ...

Cogent Biosciences Announces Positive Updated Clinical Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
- 89% ORR in TKI-therapy naïve patients; 73% ORR in all evaluable patients with 27-week median follow-up

Cogent Biosciences to Host Investor Webcast to Discuss Updated Clinical Data at ASH from the Ongoing Phase 2 APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis
WALTHAM, Mass. and BOULDER, Colo., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined...

Cogent Biosciences Appoints Rachael Easton, MD, Ph.D., VP, Head of Clinical Development
WALTHAM, Mass. and BOULDER, Colo., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined...

Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2022 Financial Results
Phase 3 PEAK trial initiated comparing bezuclastinib + sunitinib vs. sunitinib alone in second line gastrointestinal stromal tumor (GIST) patients; initial safety and pharmacokinetic data from lead-in...

Cogent Biosciences Announces Bezuclastinib Presentations at the 64th Annual American Society of Hematology (ASH) Meeting
Company to Host Virtual Investor Event on Monday, December 12 Company to Host Virtual Investor Event on Monday, December 12

Cogent Biosciences to Showcase Precision Therapy Pipeline at the EORTC-NCI-AACR Annual Meeting
WALTHAM, Mass. and BOULDER, Colo., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined ...

Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2022 Financial Results
On-track to present additional data from Phase 2 APEX trial by the end of 2022

Cogent Biosciences Announces Closing of Upsized Public Offering of Common Stock and Pre-funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares
CAMBRIDGE, Mass. and BOULDER, Colo., June 16, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically define...